New ALS drug injected into spine begins human testing
NCT ID NCT07100119
First seen Nov 18, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is injected into the spine to see if it is safe and how the body handles it. The main goal is to check for side effects, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heritage Medical Research Clinic
NOT_YET_RECRUITINGCalgary, T2N4Z6, Canada
Contact Phone: •••-•••-••••
Contact
-
Hospital Universitari i Politecnic La Fe
RECRUITINGValencia, 46026, Spain
Contact Phone: •••-•••-••••
Contact
-
Hospital Universitario de Bellvitge
RECRUITINGL'Hospitalet de Llobregat, 8907, Spain
Contact Phone: •••-•••-••••
Contact
-
London Health Sciences Centre
NOT_YET_RECRUITINGLondon, N6A 5A5, Canada
Contact Phone: •••-•••-••••
Contact
-
Montreal Neurological Institute and Hospital
RECRUITINGMontreal, H3A 2B4, Canada
Contact Phone: •••-•••-••••
Contact
-
Sunnybrook Research Institute
RECRUITINGToronto, M4N 3M5, Canada
Contact Phone: •••-•••-••••
Contact
-
UZ Leuven
RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-••••
Contact
-
Universitair Medisch Centrum Utrecht
RECRUITINGUtrecht, 3584, Netherlands
Contact Phone: •••-•••-••••
Contact
-
Universitätsklinikum Schleswig-Holstein
RECRUITINGLübeck, 23538, Germany
Contact Phone: •••-•••-••••
Contact
-
Universitätsklinikum Ulm
NOT_YET_RECRUITINGUlm, 89081, Germany
Contact Phone: •••-•••-••••
Contact
-
Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie
NOT_YET_RECRUITINGRostock, 18147, Germany
Contact Phone: •••-•••-••••
Contact
-
Walter Mackenzie Health Sciences Centre
NOT_YET_RECRUITINGEdmonton, T6G 2X8, Canada
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4256984 (given as an injection into the spine)
What this could lead to
If successful, this could point toward a treatment that slows or controls ALS progression.
What could go wrong
This is a very early Phase 1 trial with only 32 people, focused on safety. It is too soon to know if the drug works, and it may cause side effects or fail in later studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.